The Effect of Agomelatine in Behavioral and Psychological Symptoms of Dementia

키워드

참고문헌 (72)

1. Lyketsos CG, "Neuropsychiatric symptoms in Alzheimer’s disease", Alzheimers Dement, 7, pp.532~539 (2011)
2. Lyketsos CG, "Prevalence of neuropsychiatric symptoms in dementia and mild cognitive impairment : results from the cardiovascular health study", JAMA, 288, pp.1475~1483 (2002)
3. Savva GM, "Prevalence, correlates and course of behavioural and psychological symptoms of dementia in the population", Br J Psychiatry, 194, pp.212~219 (2009)
4. Chiu MJ, "Behavioral and psychologic symptoms in different types of dementia", J Formos Med Assoc, 105, pp.556~562 (2006)
5. Huang SS, "Severity and prevalence of behavioral and psychological symptoms among patients of different dementia stages in Taiwan", Arch Clin Psychiatry, 44, pp.89~93 (2017)
6. Hurt C, "Patient and caregiver perspectives of quality of life in dementia. An investigation of the relationship to behavioural and psychological symptoms in dementia", Dement Geriatr Cogn Disord, 26, pp.138~146 (2008)
7. Ferrara M, "Prevalence of stress, anxiety and depression in with Alzheimer caregivers", Health Qual Life Outcomes, 6, pp.93~ (2008)
8. Kales HC, "Rates of clinical depression diagnosis, functional impairment, and nursing home placement in coexisting dementia and depression", Am J Geriatr Psychiatry, 13, pp.441~449 (2005)
9. Wancata J, "The consequences of non-cognitive symptoms of dementia in medical hospital departments", Int J Psychiatry Med, 33, pp.257~271 (2003)
10. Ryu SH, "Persistence of neuropsychiatric symptoms over six months in mild cognitive impairment in community-dwelling Korean elderly", Int Psychogeriatr, 23, pp.214~220 (2011)
11. Usman S, "Severity and risk factors of depression in Alzheimer’s disease", J Coll Physicians Surg Pak, 20, pp.327~330 (2010)
12. Benoit M, "Apathy and depression in mild Alzheimer’s disease : a cross-sectional study using diagnostic criteria", J Alzheimers Dis, 31, pp.325~334 (2012)
13. Kwak YT, "Clinical characteristics according to depression screening tools in patients with Alzheimer’s disease : view from self, caregiver-reported and drug-intervention pattern", Geriatr Gerontol Int, 14, pp.660~666 (2014)
14. Van der Mussele S, "Prevalence and associated behavioral symptoms of depression in mild cognitive impairment and dementia due to Alzheimer’s disease", Int J Geriatr Psychiatry, 28, pp.947~958 (2013)
15. Anor CJ, "Neuropsychiatric symptoms in Alzheimer disease, vascular dementia, and mixed dementia", Neurodegener Dis, 17, pp.127~134 (2017)
16. Sadak TI, "Key neuropsychiatric symptoms in common dementias : prevalence and implications for caregivers, clinicians, and health systems", Res Gerontol Nurs, 7, pp.44~52 (2014)
17. Li XL, "Behavioral and psychological symptoms in Alzheimer’s disease", Biomed Res Int, 2014, pp.927804~ (2014)
18. Volicer L, "Relationship between symptoms of depression and agitation in nursing home residents with dementia", Int J Geriatr Psychiatry, 27, pp.749~754 (2012)
19. Van der Mussele S, "Agitation-associated behavioral symptoms in mild cognitive impairment and Alzheimer’s dementia", Aging Ment Health, 19, pp.247~257 (2015)
20. Cohen-Mansfield J, "Agitated behavior in persons with dementia : the relationship between type of behavior, its frequency, and its disruptiveness", J Psychiatr Res, 43, pp.64~69 (2008)
21. Van der Mussele S, "Depression in mild cognitive impairment is associated with progression to Alzheimer’s disease : a longitudinal study", J Alzheimers Dis, 42, pp.1239~1250 (2014)
22. Mitka M, "CMS seeks to reduce antipsychotic use in nursing home residents with dementia", JAMA, 308, pp.119~ (2012)
23. Wetzels RB, "Prescribing pattern of psychotropic drugs in nursing home residents with dementia", Int Psychogeriatr, 23, pp.1249~1259 (2011)
24. Richter T, "Prevalence of psychotropic medication use among German and Austrian nursing home residents : a comparison of 3 cohorts", J Am Med Dir Assoc, 13, pp.187~ (2012)
25. Preuss UW, "Treatment of behavioral and psychological symptoms of dementia : a systematic review", Psychiatr Pol, 50, pp.679~715 (2016)
26. Kales HC, "Assessment and management of behavioral and psychological symptoms of dementia", BMJ, 350, pp.h369~ (2015)
27. Huang JP, "Clinical textbook of geriatric psychiatry (Chinese version)", pp.105~ (2011), HO-CHI
28. Schneider LS, "Risk of death with atypical antipsychotic drug treatment for dementia : meta-analysis of randomized placebo-controlled trials", JAMA, 294, pp.1934~1943 (2005)
29. Schneider LS, "Efficacy and adverse effects of atypical antipsychotics for dementia : meta-analysis of randomized, placebo-controlled trials", Am J Geriatr Psychiatry, 14, pp.191~210 (2006)
30. Kales HC, "Risk of mortality among individual antipsychotics in patients with dementia", Am J Psychiatry, 169, pp.71~79 (2012)
31. Lyketsos CG, "Treating depression in Alzheimer disease : efficacy and safety of sertraline therapy, and the benefits of depression reduction : the DIADS", Arch Gen Psychiatry, 60, pp.737~746 (2003)
32. Pollock BG, "A double-blind comparison of citalopram and risperidone for the treatment of behavioral and psychotic symptoms associated with dementia", Am J Geriatr Psychiatry, 15, pp.942~952 (2007)
33. Leonpacher AK, "Effects of citalopram on neuropsychiatric symptoms in Alzheimer’s dementia : evidence from the CitAD study", Am J Psychiatry, 173, pp.473~480 (2016)
34. Henry G, "Efficacy and tolerability of antidepressants in the treatment of behavioral and psychological symptoms of dementia, a literature review of evidence", Am J Alzheimers Dis Other Demen, 26, pp.169~183 (2011)
35. Culo S, "Treating neuropsychiatric symptoms in dementia with Lewy bodies : a randomized controlled-trial", Alzheimer Dis Assoc Disord, 24, pp.360~364 (2010)
36. Farina N, "What is the therapeutic value of antidepressants in dementia? A narrative review", Int J Geriatr Psychiatry, 32, pp.32~49 (2017)
37. Porsteinsson AP, "Effect of citalopram on agitation in Alzheimer disease : the CitAD randomized clinical trial", JAMA, 311, pp.682~691 (2014)
38. Drye LT, "Changes in QTc interval in the citalopram for agitation in Alzheimer’s disease(CitAD)randomized trial", PLoS One, 9, pp.e98426~ (2014)
39. Banerjee S, "Sertraline or mirtazapine for depression in dementia(HTA-SADD) : a randomised, multicentre, double-blind, placebo-controlled trial", Lancet, 378, pp.403~411 (2011)
40. Howland RH, "Critical appraisal and update on the clinical utility of agomelatine, a melatonergic agonist, for the treatment of major depressive disease in adults", Neuropsychiatr Dis Treat, 5, pp.563~576 (2009)
41. Demyttenaere K, "Agomelatine : a narrative review", Eur Neuropsychopharmacol, 21(Suppl 4), pp.S703~S709 (2011)
42. Landolt HP, "Antagonism of serotonergic 5-HT2A", 2C receptors : mutual improvement of sleep, cognition and mood?, 2009, pp.29, 1795~1809
43. Hardeland R, "Melatonin in aging and disease-multiple consequences of reduced secretion, options and limits of treatment", Aging Dis, 3, pp.194~225 (2012)
44. Dagyte G, "Chronic stress and antidepressant agomelatine induce region-specific changes in synapsin I expression in the rat brain", J Neurosci Res, 89, pp.1646~1657 (2011)
45. Aguiar CC, "Effects of agomelatine on oxidative stress in the brain of mice after chemically induced seizures", Cell Mol Neurobiol, 33, pp.825~835 (2013)
46. Molteni R, "Modulation of the inflammatory response in rats chronically treated with the antidepressant agomelatine", Eur Neuropsychopharmacol, 23, pp.1645~1655 (2013)
47. Avila A, "Agomelatine for depression in Parkinson disease : additional effect on sleep and motor dysfunction", J Clin Psychopharmacol, 35, pp.719~723 (2015)
48. Skånland SS, "Off-label uses of drugs for depression", Eur J Pharmacol, 865, pp.172732~ (2019)
49. De Berardis D, "Agomelatine beyond borders : current evidences of its efficacy in disorders other than major depression", Int J Mol Sci, 16, pp.1111~1130 (2015)
50. Lužný J, "Agomelatine in elderly--finally a patient friendly antidepressant in psychogeriatry?", Actas Esp Psiquiatr, 40, pp.304~307 (2012)
51. American Psychiatric Association, "Diagnostic and statistical manual of mental disorders: DSM-5", pp.31~86 (2013), American Psychiatric Association
52. Guo NW, "Chinese version and norms of the mini-mental state examination", Taiwan J Phys Med Rehabil, 16, pp.52~59 (1988)
53. Lin KN, "Cutoffscores of the cognitive abilities screening instrument, Chinese version in screening of dementia", Dement Geriatr Cogn Disord, 14, pp.176~182 (2002)
54. Overall JE, "The brief psychiatric rating scale", Psychol Rep, 10, pp.799~812 (1962)
55. Sultzer DL, "Clinical symptom responses to atypical antipsychotic medications in Alzheimer’s disease : phase 1 outcomes from the CATIE-AD effectiveness trial", Am J Psychiatry, 165, pp.844~854 (2008)
56. Guy W, "ECDEU assessment manual for psychopharmacology", pp.218~222 (1976), U.S. Dept. of Health, Education, and Welfare, Public Health Service, Alcohol, Drug Abuse, and Mental Health Administration, National Institute of Mental Health, Psychopharmacology Research Branch, Division of Extramural Research Programs
57. Kaufer DI, "Validation of the NPI-Q, a brief clinical form of the Neuropsychiatric Inventory", J Neuropsychiatry Clin Neurosci, 12, pp.233~239 (2000)
58. Cerejeira J, "Behavioral and psychological symptoms of dementia", Front Neurol, 3, pp.73~ (2012)
59. "Clinical practice guidelines and principles of care for people with dementia" (2016)[URL]
60. Ford AH, "Neuropsychiatric aspects of dementia", Maturitas, 79, pp.209~215 (2014)
61. Vermeiren Y, "Brain region-specific monoaminergic correlates of neuropsychiatric symptoms in Alzheimer’s disease", J Alzheimers Dis, 41, pp.819~833 (2014)
62. Pinto T, "Revisiting the cholinergic hypothesis of behavioral and psychological symptoms in dementia of the Alzheimer’s type", Ageing Res Rev, 10, pp.404~412 (2011)
63. Ooms S, "Treatment of sleep disorders in dementia", Curr Treat Options Neurol, 18, pp.40~ (2016)
64. McCleery J, "Pharmacotherapies for sleep disturbances in Alzheimer’s disease", Cochrane Database Syst Rev, (3), pp.CD009178~ (2014)
65. Nie L, "Melatonin ameliorates anxiety and depression-like behaviors and modulates proteomic changes in triple transgenic mice of Alzheimer’s disease", Biofactors, 43, pp.593~611 (2017)
66. Harrison F, "Apathy in dementia : systematic review of recent evidence on pharmacological treatments", Curr Psychiatry Rep, 18, pp.103~ (2016)
67. Callegari I, "Agomelatine improves apathy in frontotemporal dementia", Neurodegener Dis, 16, pp.352~356 (2016)
68. Kazui H, "Differences of behavioral and psychological symptoms of dementia in disease severity in four major dementias", PLoS One, 11, pp.e0161092~ (2016)
69. Chiu PY, "Visual hallucinations in Alzheimer’s disease is significantly associated with clinical diagnostic features of dementia with Lewy bodies", PLoS One, 12, pp.e0186886~ (2017)
70. El Haj M, "Inhibitory deterioration may contribute to hallucinations in Alzheimer’s disease", Cogn Neuropsychiatry, 20, pp.281~295 (2015)
71. Perrault A, "Review of outcome measurement instruments in Alzheimer’s disease drug trials : psychometric properties of behavior and mood scales", J Geriatr Psychiatry Neurol, 13, pp.181~196 (2000)
72. Conn D, "Assessment of behavioural and psychological symptoms associated with dementia", Can J Neurol Sci, 34(Suppl 1), pp.S67~S71 (2007)

관련 논문AI추천